Head of Research and Early Development
Dr Rachel Gurrell has more than 20 years’ experience in neuroscience research and development with expertise at both the laboratory bench and in the clinic. Dr Gurrell has held multiple leadership roles, including leading programs developing IND-enabling and preclinical regulatory packages, and has also led design, execution, and strategic direction for multiple clinical trials across diverse neuroscience indications. Dr Gurrell has held roles at Merck, Pfizer, and Cerevel Therapeutics, most recently leading a dual indication program into Phase 2 clinical trials and heading the Translational Medicine and Biomarker discipline. Dr Gurrell has a particular passion for using biomarker-enabled approaches to increase confidence in rationale and dose selection, and to provide early signals of efficacy to enable data-driven decision-making. Dr Gurrell has a degree in pharmacology from the University of Sheffield and a doctorate in neuropharmacology from the Kingston University, London.